ProCE Banner Activity

CompLEEment-1: Updated Results From the Phase IIIb Study of Ribociclib Plus Letrozole in HR+, HER2- Advanced Breast Cancer

Slideset Download
Conference Coverage
Ribociclib plus letrozole appears safe and effective as first-line endocrine therapy in an expanded patient population with HR+, HER2- advanced breast cancer regardless of menopausal status.

Released: June 01, 2020

Expiration: May 31, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono